Explore
Validate
LearnPA5-40834
antibody from Invitrogen Antibodies
Targeting: SMARCB1
BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5, SNF5L1, Snr1
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [2]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-40834 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- SMARCB1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Peptide sequence: RGSLYKRYPS LWRRLATVEE RKKIVASSHG KKTKPNTKDH GYTTLATSVT
- Concentration
- 0.5 mg/mL
Submitted references Chromatin Remodeling of Colorectal Cancer Liver Metastasis is Mediated by an HGF-PU.1-DPP4 Axis.
Wang L, Wang E, Prado Balcazar J, Wu Z, Xiang K, Wang Y, Huang Q, Negrete M, Chen KY, Li W, Fu Y, Dohlman A, Mines R, Zhang L, Kobayashi Y, Chen T, Shi G, Shen JP, Kopetz S, Tata PR, Moreno V, Gersbach C, Crawford G, Hsu D, Huang E, Bu P, Shen X
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021 Oct;8(19):e2004673
Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2021 Oct;8(19):e2004673
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of human thymus cells using an anti-SMARCB1 polyclonal antibody (Product # PA5-40834).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry (paraffin-embedded) analysis of human alveolar tissue using an anti-SMARCB1 polyclonal antibody (Product # PA5-40834).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry (paraffin-embedded) analysis of human liver tissue using an anti-SMARCB1 polyclonal antibody (Product # PA5-40834).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 HGF upregulates DPP4 through activaton of PU.1. A) Dotplot of pathway analysis on enriched accessible chromatin regions in HT29 liver metatases. B) Western blots showing PU.1 expression level in HT29 or CRC57 cells treated with or without HGF. C) Western blots showing PU.1 phosphorylation in HT29 or CRC57 cells treated with or without HGF or the c-Met inhibitor PHA665752. D,E) Western blots showing that PU.1 complexed with D) C/EBP alpha and - beta and E) SMARCB1. F) ChIP-qPCR showing relative H3K27ac, H3K4me1, H3K4me3, and H3K9ac enrichments in HT29 or CRC57 cultured in RPMI1640 media supplemented with or without 100 ng mL -1 HGF. G) Western blots showing the expressions of DPP4 in HT29 or CRC57 carrying scrambled (control) or PU.1 knockdown shRNA cultured in RPMI media supplemented with or without 100 ng mL -1 HGF. H,I) Images and quantification of H) bioluminescence and I) survival analysis of NSG mice spleen-injected with luciferase-labeled HT29 cells receiving i.p. administered PBS (control) or the HGF inhibitor Norleual. Data represent the mean +- s.d. in (F) and (H). p -values were calculated based on Student's t -test (F) and log-rank test in (I). * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
